Introduction
Leukocyte adhesion deficiency (LAD)' is an inherited disorder of leukocyte function that is associated with recurrent lifethreatening infections (1) (2) (3) . Leukocytes from affected patients are deficient in three cell surface glycoproteins that mediate important cell-cell interactions (4) . These glycoproteins are dimeric molecules that contain a common subunit, called CD1 8, and one of three unique a subunits including CDl la (LFA-1), CDl lb (Mol), and CDl lc (p1 50,95). The molecular basis ofLAD appears to be an abnormality in the expression or function of the shared subunit CDl8 (5-7).
The only effective cure for LAD is allogeneic bone marrow transplantation (8) . The relative success ofthis therapeutic modality suggests an alternative approach based on somatic gene therapy. This strategy would involve stably transducing a functional CDl 8 gene into autologous hematopoietic stem cells ex vivo which would be used to reconstitute a normal hematopoietic system in the setting of an autologous bone marrow transplant. As a first step towards the development of this therapy we described, in a previous study, the use ofrecombinant retroviruses to transduce a normal CDl8 gene into EBV-transformed lymphoblasts of an LAD patient (9) . Retroviral-mediated gene transfer into these cells led to reconstitution of cell surface expression of CD 1 Ia/CD 18 and correction of functional defects in adhesion.
Despite these encouraging results in vitro, many important questions remain about the feasibility ofgene therapy for LAD. Is it possible to achieve therapeutic levels of CDl 8 expression in appropriate lineages following reconstitution with retroviral transduced stem cells? Furthermore, will recombinant derived CDl 8 be regulated appropriately in differentiated hematopoietic cells oftransplant recipients? Finally, will constitutive and/ or ectopic expression ofCD 18 affect hematopoietic reconstitution or lead to disease?
As part of our goal to design a safe and effective genetic treatment for LAD, we describe in this report an in vivo murine model of human CD 18 (14) . A monoclonal antibody to human CD18 (IB4, ref. 15 ) was conjugated to biotin as described (16 Blood was harvested 6 wk after transplantation and analyzed for cell surface expression of human CD18 as described in Methods. The analyses were performed on a subpopulation of nucleated cells that were enriched for granulocytes based on forward and ninety degree light scatter. This panel summarizes the expression of CD18, in terms of percentage oftotal granulocytes that specifically stained with the human CD18 MAb (i.e., < 1%, 1-5%, 6-25%, and > 25%), in animals transplanted with BA-CD18 transduced (shaded bars) or CMV-BA-CD18 transduced (stippled bars) bone marrow.
transcriptional unit (11); the vectors differ by the presence (CMV-BA-CD18) or absence (BA-CD18) of enhancer sequences derived from the immediate early gene ofcytomegalovirus. Fig. 1 A presents the structures of these vectors. Bone marrow was isolated from C3H/HeJ mice, transduced with either CMV-BA-CD18 or BA-CD18 ecotropic virus, and transplanted into syngeneic lethally irradiated recipients (40 recipient animals for each virus) as described (11) . Approximately 75% of the animals survived the transplant. This rate ofsurvival is similar to that achieved with retroviruses expressing other genes (for example, ref. 1 1) suggesting that CD18 gene transfer had no apparent effect on hematopoietic reconstitution. Animals that survived the transplant (60/80) were subsequently analyzed for expression of human CD 18 in peripheral blood leukocytes by flow cytometry using a human CD1 8 MAb. In these analyses, nucleated cells were separated into lymphocyte or granulocyte enriched fractions based on light scatter properties; Fig. 1 granulocyte enriched fractions. Analysis of blood harvested 6 wk after transplantation revealed significant human CD 18 expression in granulocytes from 25 of 60 surviving mice. The number ofcells expressing human CD 18 ranged from undetectable to 70% of total granulocytes and did not qualitatively change when analyzed at 6 mo (22 of 60 animals assayed) following transplantation. The lymphocyte gated fraction consistently demonstrated 5-to 10-fold fewer CD18 expressing cells than the granulocyte gated fraction. Analyses of peripheral blood from the highest expressing animals for the presence of replication competent virus were consistently negative (11) . These studies suggest that a substantial number of animals have been partially reconstituted with retroviral transduced hematopoietic stem cells. Two animals that expressed human CD18 in > 25% of peripheral blood granulocytes 6 mo after transplantation were characterized further. Leukocytes were separated into granulocyte and lymphocyte enriched fractions and analyzed by two color flow cytometry for the coexpression ofhuman CD 18 with several murine leukocyte antigens including murine CD 18, CDl la, CD1 lb (a granulocyte/monocyte marker), GR-1 (a granulocyte marker), and murine CD45r (a murine B lymphocyte marker). Data from the animal that expressed human CD1 8 in 14% ofthe lymphocyte fraction and 75% ofthe granulocyte fraction (animal 15-6, reconstituted with CMV-BA-CD18 transduced bone marrow) are summarized in Table I and selected histograms are presented in Fig. 2 . Direct evidence to support the expression ofhuman CD1 8 in granulocytes was provided in experiments that detected human CD18 in 50-75% of cells expressing the lineage specific markers, GR-1 and CDl lb. Human CD18 was detected in 3% of CD45r positive cells indicating that the recombinant gene was active in a small subpopulation of lymphocytes. Finally, expression of human CD18 in granulocytes had no apparent effect on the expression of endogenous CD1 la, CDl lb, and CD18 relative to bone marrow transplant recipients in which human CD18 was not expressed (data not shown).
Selected animals were euthanized and various tissues were harvested and analyzed for human CD18 expression by two color flow cytometry. The flow cytometric analysis ofhematopoietic tissues demonstrated consistent lineage-specific expression of human CD18 with substantially greater expression in granulocytes than lymphocytes. This could. be caused by selective reconstitution of the myeloid compartment with transduced cells or diminished transgene expression in the lymphoid compartment of an animal fully reconstituted with transduced cells. In (Table I) a analysis. DNA was prepared from each tissue, restri4 fractionated in an agarose gel, and subjected to DNM using human CD18 cDNA as a probe (9) . DNA (10, an attempt to elucidate the basis for this apparent lineage restriction, hematopoietic tissues were analyzed for proviral DNA (Fig. 3) . Total cellular DNA was prepared from each tissue, restricted with Kpnl, fractionated in an agarose gel, and subjected to DNA blot analysis using human CD18 cDNA as a probe (9) . DNA blot analysis of total cellular DNA from animal 15-6 demonstrated equal and abundant quantities of unrearranged proviral DNA in spleen, thymus, lymph node, and bone marrow (approximately one proviral copy/cell). (Fig. 4 C) and CDl lb (Fig. 4 B) increased threefold and four-to nd DNA blot sixfold, respectively, following incubation with PMA, while icted with Kpnl, human CD18 increased four-to fivefold (Fig. 4 A) . Human K blot analysis granulocytes demonstrated similar increases in CD18 (Fig. 4A ) ug) was obtained and CDl lb (Fig. 4 B) 
